期刊文献+

DPP-4抑制剂对2型糖尿病心血管并发症危险因素的干预作用及机制 被引量:9

在线阅读 下载PDF
导出
摘要 2型糖尿病是一种慢性代谢性疾病,高血压、高血脂、肥胖、血管内皮功能障碍等是糖尿病心血管并发症的危险因素。二肽基肽酶4(DPP-4)抑制剂是一类治疗糖尿病的新型药物,可针对糖尿病心血管并发症的多种危险因素、从多个方面起到干预作用。DPP-4抑制剂可提高体内胰高糖素样肽-1(GLP-1)和葡萄糖依赖性促胰岛素分泌多肽(GIP)的浓度并延长其活性,抑制胰高糖素分泌,降低血糖,而内源性GLP-1能减少空腹和餐后游离脂肪酸水平、抑制下丘脑摄食中枢病理性亢进等从而减轻体质量;DPP-4抑制剂可增加循环中内皮前体细胞数量,使内皮依赖的血管舒张功能得到改善,并可使外周血管扩张、外周阻力减小从而达到降低血压的作用。目前关于DPP-4抑制剂的心血管安全性的大型前瞻性研究正在进行,将为DPP-4抑制剂的心血管保护作用提供更加充分的循证医学证据。
出处 《山东医药》 CAS 北大核心 2015年第27期101-103,共3页 Shandong Medical Journal
  • 相关文献

参考文献4

二级参考文献54

  • 1Ford ES. Risks for all - cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005 ;28 (7) : 1769 - 1778.
  • 2Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity - onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991;151(6) :1141 - 1147.
  • 3Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12 - yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993 ; 16 ( 2 ) : 434 - 444.
  • 4Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360(2) :129 -39.
  • 5ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358(24) :2560 -2572.
  • 6ACCORD Study Group, Gerstein HC, Miller ME, et al. Long - term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011 ;364(9) :818 -828.
  • 7Green JB. The dipeptidyl peptidase - 4 inhibitors in type 2 diabetes mellitus: cardiovascular safety. Postgrad Med 2012;124(4) : 54 - 61.
  • 8Ban K, Noyan - Ashraf MH, Hoefer J, et al. Cardioprotectire and vasodilatory actions of glucagon - like peptide 1 receptor are mediated through both glucagon - like peptide 1 receptor - dependent and - independent pathways. Circulation 2008 ; 117 ( 18 ) :2340 - 2350.
  • 9Eeg - Olofsson K, Cederholm J, Nilsson PM, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia 2009 ;52( 1 ) ;65 -73.
  • 10Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel - group, open -label trial. Int J Clin Pratt 2011 ;65(4) :397 -407.

共引文献9

同被引文献102

引证文献9

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部